We also demonstrate that transient CDK9 inhibition, a clinically validated strategy to inhibit malignant growth by depleting short-lived labile proteins like MCL1 (22, 23), similarly inhibits tumor cell survival and growth in PBRM1-deficient ccRCC but not WT. Here, CDK9 is linked to neoplasm.